Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (16) , 4641-4651
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies. The metabolomic approaches are developed to discover the novel biomarkers of PDAC.Keywords
This publication has 49 references indexed in Scilit:
- Metabolic system alterations in pancreatic cancer patient serum: potential for early detectionBMC Cancer, 2013
- HMDB 3.0—The Human Metabolome Database in 2013Nucleic Acids Research, 2012
- Diabetes and pancreatic cancerMolecular Carcinogenesis, 2011
- The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathologyMolecular Aspects of Medicine, 2011
- Serum biomarkers for improved diagnostic of pancreatic cancer: a current overviewJournal of Cancer Research and Clinical Oncology, 2010
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status reportAnnals of Oncology, 2009
- Clinical Applications of Metabolomics in Oncology: A ReviewClinical Cancer Research, 2009
- New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancerThe Lancet Oncology, 2009
- Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high‐resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysisCancer Science, 2007
- 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic dataXenobiotica, 1999